Rigel Pharmaceuticals (RIGL) Interest Expenses (2010 - 2026)

Rigel Pharmaceuticals' Interest Expenses history runs 10 years deep, the most recent figure standing at $1.4 million for Q1 2026.

• In Q1 2026, Interest Expenses fell 22.67% year-over-year to $1.4 million; the TTM figure through Mar 2026 stood at $6.9 million (down 12.63% YoY), while the FY2025 annual figure was $7.3 million, down 7.55% from the prior year.
• Interest Expenses was $1.4 million for Q1 2026 at Rigel Pharmaceuticals, down from $1.7 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $2.1 million in Q3 2024 to a low of $569000.0 in Q2 2022.
• Historically, Interest Expenses has averaged $1.6 million across 5 years, with a median of $1.9 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Interest Expenses slumped 67.65% in 2022, then soared 227.24% in 2023.
• A 5-year view of Interest Expenses shows it stood at $1.1 million in 2022, then surged by 72.27% to $1.9 million in 2023, then gained by 2.52% to $2.0 million in 2024, then slipped by 13.09% to $1.7 million in 2025, then retreated by 15.66% to $1.4 million in 2026.
• The last three Interest Expenses figures came in at $1.4 million (Q1 2026), $1.7 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.